Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novo Nordisk A/S (NVO) vs SoFi Technologies Inc (SOFI) Price & Performance

Novo Nordisk A/STrade
SoFi Technologies IncTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs SoFi Technologies Inc — how do they compare? Novo Nordisk A/S trades at $46.1 (market cap $207.85B), while SoFi Technologies Inc trades at $17.74 (market cap $23.22B). The key difference: Novo Nordisk A/S is far larger — about 9× SoFi Technologies Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while SoFi Technologies Inc pays none. Which is the better fit depends on your goals.

NVOSOFI
Market Cap
$207.85B$23.22B
Sector
HealthFinancials
52-Week High
$63.98$32.21
52-Week Low
$35.29$15.15
Enterprise Value
$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.

The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.

SoFi Technologies Inc

SOFI trades at $18.12, down 1.41% today, with a bullish technical signal and recent earnings beats. Revenue grew to $3.61B in 2025, with a net income margin of 14.78%. The stock is supported by strong member growth and a consensus price target of $19.50, though negative operating cash flow and high valuation ratios present challenges.

Outlook is cautiously optimistic with growth potential from digital banking expansion, but risks include persistent negative cash flow, competitive pressures, and sensitivity to interest rate changes. Analyst sentiment is mixed, with 33% buy ratings highlighting upside, while high P/E of 36.69 warrants caution for value-focused investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO

About SoFi Technologies Inc

SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.

Read more on SOFI